|1.||Park, Eun-Jung: 1 article (12/2005)|
|2.||Kim, Won Bae: 1 article (12/2005)|
|3.||Hong, Ji-Young: 1 article (12/2005)|
|4.||Min, Hye-Young: 1 article (12/2005)|
|5.||Lee, Sang Kook: 1 article (12/2005)|
|6.||Park, Hyen Joo: 1 article (12/2005)|
|7.||Chung, Hwa-Jin: 1 article (12/2005)|
|8.||Kim, Soon Hoe: 1 article (12/2005)|
|9.||Lee, Hak Sung: 1 article (01/2004)|
|10.||Lee, Minjun: 1 article (01/2004)|
|1.||Hepatocellular Carcinoma (Hepatoma)
12/19/2005 - "Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases."
12/19/2005 - "In this study, we examined the influence of DA-125, a new anthracyclin analog, on the gene expression of MMPs (MMP-2, MMP-9 and MT1-MMP), tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-2) and in vitro invasiveness of human fibrosarcoma cells. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/01/1997 - "Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin."
09/01/1997 - "The study was undertaken to investigate the antitumor activity of DA-125, a promising new analogue of adriamycin (ADM) containing fluorine, against human gastric and pulmonary adenocarcinoma cell lines and their sublines resistant to ADM and cisplatin (CDDP) by MTT assay. "
12/19/2005 - "These data, therefore, provide direct evidence for the role of DA-125 as a potential cancer chemotherapeutic agent, which can markedly inhibit the invasive capacity of malignant cells. "
12/19/2005 - "In addition, DA-125 inhibited the invasion, motility and cell migration, and colony formation of tumor cells. "
06/01/1998 - "Single dose of DA-125, 20 (n = 3), 40 (n = 3), 60 (n = 3), 80 (n = 6), or 100 (n = 6) mg/m2 body surface area, was administered intravenously in 5 min to 21 patients with various types of cancer as phase I clinical trial. "
01/01/1997 - "Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines."
01/01/2004 - "DA-125, a novel derivative of adriamycin, is known for its anti-cancer activity. "
|3.||Tissue Inhibitor of Metalloproteinases (TIMP)
|9.||tranilast (N 5')